Skip to main content
SpringerLink
Log in

Impact of mergers & acquisitions on research productivity within the pharmaceutical industry

  • Published:
Scientometrics Aims and scope Submit manuscript

Abstract

Several major econometric studies have looked at mergers and acquisitions (M&As) across various industries and concluded that, in general, there is no synergy created or released by M&A activity. This investigation concentrates upon research and development (R&D) performance in the pharmaceutical industry to examine the impact of M&A activity on corporate productivity. Findings indicate that, when compared to those companies within the pharmaceutical industry that did not experience merger activity during comparable time periods, as well as to the industry as a whole, pharmaceutical companies that merged were able to achieve more favorable post-merger productivity scores than were attained prior to their merger.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Barrett, A., Capell, K. (2002, July 29). Big pharma: Getting too big for its own good? Business Week, 74.

  • Bruner, R. (1999, Dec 13). M&As under scrutiny. Electronic News, 45(50): 16-19.

    Google Scholar 

  • Comanor, W. S. (1965, May). Research and technical change in the pharmaceutical industry. The Review of Economics and Statistics, 47(2): 182-190.

    Google Scholar 

  • Graves, S. B., Langowitz, N. S. (1993). Innovative productivity and returns to scale in the pharmaceutical industry. Strategic Management Journal, 14(3): 593-605.

    Google Scholar 

  • Jensen, E. J. (1987). Research expenditures and the discovery of new drugs. Journal of Industrial Economics, 36: 83-95.

    Google Scholar 

  • Koenig, M. E. D. (1992). The information environment and the productivity of research. In: H. Collier (Ed.), Recent Advances in Chemical Information (pp. 133-143). London: Royal Society of Chemistry, and In: I. K. Ravichandra Rao (Ed.) (1992), Informetrics-91: Selected Papers from the Third International Conference on Informetrics (pp. 261–288). Bangalore Sarada Ranganathan Endowment for Library Science. Also reprinted in Grimshaw, A. (Ed.) (1995), Information Culture and Business Performance (Information Strategy Report 2, prepared for the British Library by Hertis Information and Research). Hatfield, Hertfordshire, United Kingdom: University of Hertfordshire Press.

    Google Scholar 

  • Koenig, M E. D. (1983). A bibliometric analysis of pharmaceutical research. Research Policy, 12(1): 15-36.

    Google Scholar 

  • Koenig, M.E.D., Gans, D. J. (1975). The productivity of research effort in the U.S. pharmaceutical industry. Research Policy, 4(4): 331-349.

    Google Scholar 

  • Lasgna, L. (1972). Research regulation and development of new pharmaceuticals: Past, present and future. American Journal of Medical Science, 263: 9-19, 67–78.

    Google Scholar 

  • Making a meal of mergers. (1994, September 10). The Economist, 332(7880): 87-88.

  • McMillan, S. G., Hamilton, R. D. III. (2000). Using bibliometrics to measure firm knowledge: An analysis of the U.S. pharmaceutical industry. Technology Analysis and Strategic Management, 12(4): 465-475.

    Google Scholar 

  • Mitchell, M. L., Lehn, K. (1990). Do bad bidders become good targets? Journal of Political Economy, 98(2): 372-398.

    Google Scholar 

  • Narin, F., Norma, E. Perry, R. (1987). Patents as indicators of corporate technological strength. Research Policy, 16(2–4): 143-155.

    Google Scholar 

  • Pollack, A. (2002, April 19). Despite billions for discoveries, pipeline of drugs is far from full. The New York Times: C1.

  • Schwartzman, D. (1976). Innovation in the Pharmaceutical Industry. Baltimore, MD: Johns Hopkins University Press.

    Google Scholar 

  • Shliefer, A., Vishny, R. W. (1990, August 17). The takeover wave of the 1980s. Science, 249(4970): 745-749.

    Google Scholar 

  • The trouble with mergers. (1994, September 10). The Economist, 332(7880): 13-14.

  • Thompson, D. E. (2001). Get big enough (but not too big) to source innovation: To grow in the high risk pharmaceutical industry, Lilly favors a collaborative strategy of ‘innovation leverage’ over an M&A approach. Research-Technology Management, 44(6): 22-26.

    Google Scholar 

  • Vernon, J. M., Gusen, P. (1974). Technical change and firm size: The pharmaceutical industry. Review of Economics and Statistics, 56: 294-302.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Information & Computer Science, Long Island University Brookville, NY (, USA

    Michael E. D. Koenig

  2. Center for Business Research, Long Island University, C.W. Post Campus Brookville, New York, USA, 11548

    Elizabeth M. Mezick

Authors
  1. Michael E. D. Koenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth M. Mezick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koenig, M., Mezick, E. Impact of mergers & acquisitions on research productivity within the pharmaceutical industry. Scientometrics 59, 157–169 (2004). https://doi.org/10.1023/B:SCIE.0000013304.40957.0d

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:SCIE.0000013304.40957.0d

Keywords

Search

Navigation